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Introduction 
The availability of drug information that is useful to clinicians is 
an important need for those responsible for medication use in patients. 
Physicians, pharmacists,  nurses, and patients routinely require access to 
relevant information related to rational drug therapy. The need for rapid 
access to relevant information has become increasingly important as the 
science, technology, and specialization within health care expand. Because 
of this expansion the literature has increased not only in size but also in 
complexity. 
The term drug information (e.g.,  used in drug information service, 
drug information center or drug information specialist) is defined as 
"knowledge of facts or circumstances acquired through reading, study or 
practical experience concerning the chemical substance intended for use in 
diagnosis, prevention, treatment or cure of disease or otherwise to enhance 
the physical or mental well-being of men or animals" (1). This definition 
may be expanded to include the ability to provide information to the user 
in a special manner known as a drug information service. Drug information 
service is defined as "the activities involved with accumulating, organizing, 
and retrieving drug information and may include provision of documents and 
bibliographic compilations or other medical l ibrary functions" (1). 
Evolution of Drug Literature 
In the late 17th century the first scientific periodicals were estab­
lished to allow the publication of scientific papers in these journals 
instead of in books (2). In the middle 1930s significant changes in the 
2 
numbers of medical agents began with the introduction of sulfonamides in 
the 1930s and penicillin and other antibiotics in the 1940s (1). The 
growth of chemistry and biological sciences helped the physician to diag­
nose disease and to prescribe an increasing number of drugs for disease-
specific therapy (3). By 1945 the availability of new synthetic drugs 
was limited, but between 1948-1960 the increasing number of pharmaceuti­
cal manufacturers: led to a significant increase in new drugs. Associ­
ated with the increased number of drugs was an increase in the volume of 
medical and pharmaceutical l i terature (1). A congressional report related 
to the drug literature was published in 1S63 and included the following 
statements (1, 4, 5): 
1. The scientific and medical l i terature is vast and complex and 
i t  is not possible to define the "drug literature." 
2. Drug literature includes primary journals, abstracting and 
indexing publications, books, monographs, patents, proceedings, reviews, 
package inserts,  as well as such related forms as house organs, news­
letters, promotional l i terature, analyses by consultant services, etc. 
3. There is no simple or single solution to the "problem" of drug 
literature because i t  is really a complex of problems, requiring a com­
plex of efforts for solutions. 
Much important drug information is not "published"; information 
on adverse reactions to drugs, much of which is not published, is a lead­
ing example. 
5. Competent evaluation of masses of drug information is particu­
larly necessary. 
In 1963 the Kefauver-Harris (New Drug) Amendments were published 
which required that new drugs must be proven safe and effective prior to 
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receiving Food and Drug Administration approval for marketing. This 
amendment led to revisions of investigational drug regulations, expanded 
the need for clinical evaluation of drugs, and greatly increased the 
drug information literature. For example, i t  has been estimated that 
about 2,000,000 new reports related to health care and research are pub­
lished per year and that 25-50 percent of these reports include informa­
tion about drugs. Of these, only about 200,000 are in traditional 
"pharmaceutical" publications (4). The balance of these publications 
are contained in medical and other clinical publications. To respond to 
the increase in size and complexity of the drug literature, numerous 
drug information services and systems have been developed during the 
past twenty years. Although these services and systems are diverse in 
design, their objectives are similar and rather simple, and include pro­
viding service and education regarding medication use. A principle 
objective associated with a drug information service is to provide rapid 
access to relevant information about drug use. The ultimate goal of the 
service is to help provide answers related to medication use in patients, 
and includes considerations such as dosage adjustments, drug of choice, 
pharmacology, side effects, adverse reactions, or interactions. A second 
objective associated with drug information services is to educate health 
care providers and patients on rational drug therapy. Physicians, pharma 
cists,  nurses, other health professionals, and patients may participate 
in seminars, lectures, discussions, or receive publications in order to 
learn the latest information on appropriate drug use. 
Types of Drug Literature 
There are three classes of drug literature as follows: 
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!• Primary literature (sources). These sources are considered the 
most specific type of information. They appear regularly in journals or 
"periodicals" and contain the original papers or articles that provide 
the initial reporting of results of clinical and other investigations. 
Articles in the primary literature focus on many aspects of drugs, such 
as drug therapy evaluations, side effects, and adverse reactions. It  
was estimated that in 1963 the number of world scientific periodicals was 
50,000, of which 30,000 are still  active. These journals contain about 
six million scientific papers. The estimated number of papers has 
increased at a rate of about 500,000 per year, 10 percent of which are 
biomedical in nature (2). 
2. Secondary literature (sources). These sources use various for­
mats and serve as a guide to the primary literature. The examples of 
secondary literature include abstracting and indexing publications such 
as International Pharmaceutical Abstracts, Index Medicus, deHaen Orugs 
In Use and Iowa Drug Information Service. Oatfield and Emilia (6) have 
listed 75 secondary sources which are helpful in searching the drug 
literature. Watanabe et al.  (7) have mentioned that "secondary reference 
sources are not necessarily restricted in their scope to certain types 
of information. Exceptions, however, are Adverse Reaction Titles from 
the Excerpta Medica Foundation, Clin Alert from Science Editor, Inc. and 
Toxicity Bibliography from Index Medicus of the National Library of 
Medicine. These sources are more specific for information on the adverse 
reactions and toxicities of drugs." 
A relatively new type of secondary source is called the automated 
drug information service. These automated services are designed to pro­
vide and use two types of information (8). The information monitoring 
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type maintains a patient profile that includes all  medications taken by 
the patient.  When a new drug is given to the patient,  i t  can be checked 
automatically by the service to determine if there is a potential for 
adverse reactions, interactions, or any other problems. The Information 
monitoring type has been developed for use in inpatient as well as ambu­
latory care settings (9-11). Examples of this type include the systems 
of Cohen at Stanford University Medical Center (9) and Maronde and Associ­
ates at the Los Angeles County-University of Southern California Medical 
Center (12). The second type of automated services is designed to answer 
questions. This type has a computerized drug information storage device 
where the information is stored and is available to the user. By using 
a combination of key words to define the question, the computer provides 
one or more possible "answers" to the question. The examples of this 
type include Excerota Medica, Drugdoc (EMD) and Medlars. 
3 General Reference Works. These sources contain documented infor­
mation from the primary literature in condensed and compact format. Gen­
eral references provide drug information in specific areas. They do not 
appear in series at regular intervals so they may not contain current 
information from the primary literature. In addition general references 
differ from the secondary literature in format and type. Examples of 
general references are textbooks, review articles and reference works (7). 
Drug Information Needs 
1. Physician. One of the major users of drug information is the 
physician, who must make patient-specific drug therapy decisions. Chang­
ing therapeutic approaches and emerging areas of specialty, such as 
oncology, have placed an increased burden on the physician to seek timely 
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and appropriate sources of drug information. In many instances clinical 
pharmacists may serve as the most accessible source of drug information. 
Specific types of information required by the physician may include 
choice of therapy, dosage, toxicity, side effects, mechanism of action, 
interactions and pharmacokinetics. In certain situations the information 
requested is not easily acquired, e.g.,  information on investigational 
drugs. Regardless of the situation, drug literature, manufacturers'  
material,  books, and specialized indices serve as the major sources of 
information to answer the physicians'  questions. A special concern is 
to use the drug information resource that is most effective and efficient 
for the specific question under consideration. Gaining access to the 
appropriate source of information on a timely basis is critical if the 
physician is to respond appropriately to the changing medical needs of 
the patient.  Because of the need for a timely response, using a clinical 
pharmacist or drug information center as the physician's intermediary has 
been recommended (1). 
2. Pharmacist.  The pharmacist 's needs for drug information can be 
related to the following: 
A. The usual dosage, commercial availability, stability, 
storage conditions or price of the prescription medications which he is 
dispensing. This kind of information is generally termed pharmaceutical 
and may be obtained from the product manufacturer or from the various 
publications that specialize in this kind of information. Examples of 
these include the Physician's Desk Reference, Facts and Comparisons; and 
B. Questions which are usually asked by physicians, nurses, 
patients, and others, about the drug. To answer such questions the 
pharmacist should have the ability to utilize appropriately any of the 
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information sources which are available to him. In addition to prescrip­
tion drug information, the pharmacist has a special and unique need for 
information on medications available without the physician's prescrip­
tion (1). 
3. Nurses. Levine described the drug information needs of nurses 
(13). "The nurse should know the expected side effects, and therapeutic 
risks so that he/she can make intelligent decisions about giving or 
withholding a drug." The nurse needs to know the dangers of drug therapy, 
especially those associated with drug administration. In the hospitalized 
situation the nurse is the last check to insure the patient receives the 
correct drug and dose at the right time via the correct route. 
4. Patient.  The patient needs information about the medications 
he/she is taking. Such things as the drug's effects, how i t  should be 
stored, how and when i t  should be taken, side effects, etc.,  are impor­
tant to the successful treatment of the patient.  If the patient does not 
know how to take his/her medications, i t  is obvious that problems in self-
administration may occur. One of these problems is the development of 
adverse reaction to the drug, which was estimated in 1969 to cause about 
$1.5 million of hospital annual admissions (14). In 1975, adverse drug 
reactions were reported to add $3 billion to U.S. health care costs (15). 
Pharmacist 's Role 
The role of the pharmacist as a drug information specialist has 
expanded as a result of the increasing number of new drugs, and the 
research reported in the drug literature. This role is not new, for i t  
was described by Irons who wrote in the Journal of the American Medical 
Association in 1930 that a closer acquaintance and cooperation between 
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the hospital pharmacist and the members of the medical staff will be of 
mutual profit  .  .  .  and the pharmacist has not taken as large a place 
in hospital conferences as he should. His function should not cease 
with the supplying of drugs called for in a prescription and the detect­
ing of inadvertent errors of dosage, but properly should be extended in 
an informative and advisory capacity" (16). Another author wrote in 
1966 that the role of the pharmacist as a drug information specialist 
was essentially unfilled (17). Watanabe and Conner in 1978 suggested 
that the solution to the complex problem of communicating the latest 
information on drugs and their use by health care practitioners would be 
to develop clinically trained pharmacists as a source of drug informa­
tion (7). Halbert et al.  in 1977 did a survey of 90 drug information 
centers and their results showed that pharmacists "fall short in attain­
ing their full potential for producing rapid, accurate and concise infor­
mation about drugs" (18). A survey prepared for the U.S. Food and Orug 
Administration indicated that pharmacists were selected as a source for 
clinical information by less than 20 percent of the responding physi­
cians (19). There are many reasons for this shortcoming. Pearson wrote 
in 1975 "presently only a few (less than five) programs in this country 
are devoting a sufficient amount of effort to the training of drug infor­
mation specialists,  and this year at least six major drug information 
services may not be able to locate and hire qualified specialists.  In 
view of this,  i t  is obvious that the supply is far less than demand" (20). 
Another reason was indicated by Francke who wrote in 1966 "pharmacy stu­
dents do not have the opportunity to form a public health oriented self-
image because they are not in contact with those who can help them until  
their course is almost over and then i t  is almost too late. Pharmacists 
need the right type of contact early in their educational process." He 
also indicated that "students learn not only from didactic instruction 
of their professors and from the precepts of practitioners; they learn 
more enduringly from their sustained involvement with the patient,  physi­
cians, nurses, dieticians, and other members of the health-care team in 
an institution devoted to the care of the sick guided by the model of a 
clinically oriented pharmacist with whom they can readily identify" (21). 
Zellmer in 1974 suggested that "perhaps i t  is time for our profession, 
under some appropriate national leadership to expand the scope of existing 
drug information centers and create new centers as well.  Further, when 
the profession finally develops a system for certifying specialists,  hope­
fully a specialty in drug information services will be recognized. This 
would be an important factor in attaining for certain pharmacists recog­
nition as 'highly trained drug consultants '" (22). 
In general these studies cited above indicated that in the 1970s the 
pharmacist 's role as a drug information specialist was not fully devel­
oped. Since that time several responsibilities have been described as 
part of the role of the drug information pharmacist.  These responsibili­
ties include the following: 
1. Identify sources of clinical information in general: references, 
textbooks, abstracting/indexing services, and scientific journals; 
2. Interpret,  analyze and evaluate this information; 
3. Provide this information to the person who needs i t .  
Further, in order for the pharmacist to function as a drug information spe­
cialist he must enter the clinical area and serve as an interface between 
the biomedical l i terature and the clinician and his patient (2). This 
involvement in the clinical area will increase the physician's response 
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to the pharmacist as a source for clinical information. 
In a related fashion, the American Medical Association suggested 
that readjustments must be made in medical education which shift the 
emphasis from the acquisition of information to the selection, organi­
zation and evaluation of information (23). Such a suggestion implies the 
need and importance for pharmacists to be involved as drug information 
specialists and clinical consultants (1). Bell et  al.  (24) and Hull et  
al.  (25) have shown in their works that physicians will accept and use 
pharmacists as drug information specialists in patient care settings. 
Fisher and Pathak (26) indicated "that most recently graduated pharma­
cists are prepared to assume the role of drug information consultants." 
They also indicated that "one might postulate that strengthening of 
physician peer pressure could increase the use of pharmacists as a source 
of clinical drug information." 
Drug Information Centers 
The role of the pharmacist as a drug information specialist devel­
oped as an early example of the clinical responsibility of the pharmacy 
profession. The role was formalized with the development of drug infor­
mation centers. The first drug information center in the United States 
was established in 1962 at the University of Kentucky by Burkholder (27). 
Today there are over 90 centers throughout the country employing over 
200 full time and part-time pharmacists (7). 
The needs and purpose of a drug information center were described 
by Francke in 1963 in "The Drug Information Center -  A Professional Need 
and Opportunity" who wrote ".  - .There is not the need so much for more 
drug information sources as there is for the organization and centraliza­
tion of information now available and for an experienced and well-qualified 
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person to disseminate i t .  No individual physician can hope to maintain 
complete sources of drug information. But each can refer to a central 
source where he may obtain information on investigational drugs, drug 
reactions, availability of drugs, comparisons and contrasts of groups of 
drugs, incompatibilities, milliequivalents, reports on individuals drugs, 
and so forth." Francke suggested that the establishment of drug infor­
mation centers by pharmacists familiar with the drug literature could 
adequately meet the drug information needs of physicians. By establish­
ing drug information centers, a small number of pharmacists trained as 
drug information specialists could meet the needs of thousands of physi­
cians serving millions of patients (28). As the concept of drug infor­
mation specialists and centers evolved, the purposes and tasks of drug 
information centers became increasingly apparent. These purposes include 
1. Providing accurate, unbiased drug information (7); 
2 .  Teaching students in medicine, dentistry, nursing, and phar­
macy (29); 
3. Providing health professionals with accurate drug information 
and answering drug-related questions (5); 
4. Maintaining and updating the information base of the center (30, 
31); 
5. Acting as an information source to the public through lectures, 
presentations or patient counseling (7); 
6. Providing services 24 hours a day, seven days a week (7); 
7. Collecting and reporting adverse drug reactions (29). 
Evaluation of Drug Information Services 
Several investigators have evaluated and compared various drug 
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information services and systems. These studies have used various 
methods and criteria to quantitatively or qualitatively predict the 
value of the services for certain information needs. Yokel et  al.  com­
pared four toxicology services (Poisindex, ToxlFile, Clinical Toxicology 
of Commercial Products and National Clearinghouse for Poison Control 
Centers).  They determined the frequency of finding entries for sub­
stances known to be involved in accidental pediatric ingestions* They 
also evaluated the extent of the content and management information, and 
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the time required to obtain the information for the four services. They 
found that Poisindex was more complete than the others. ToxiFile was 
more useful than the remaining two services, although the latter were 
judged useful in over 70 percent of accidental toxic Ingestions by chil­
dren (32). 
Another study performed by Bell evaluated different drug interaction 
publications in the retrieval and application of drug interaction infor­
mation. He indicated that the American Pharmaceutical Association's 
Evaluations of Drug Interactions and Hansten's Drug Interaction were the 
most comprehensive references. Stockley's Drug Interactions and Their 
Mechanism was considered nearly as complete. Cohen's Drug Interactions: 
A Handbook for Clinical Use. Gant's Drug Interactions Index: A Survey 
of Drug Interactions and Hartshorn's Handbook of Drug Interactions were 
deemed useful as an added check if  an interaction suspected clinically 
was not included in any of the former groups (33). 
Tourville and McLeod have compared the clinical utility of Inter­
national Pharmaceutical Abstracts (I.P.A.), Iowa Drug Information Service 
(I.D.I.S.),  and deHaen Drugs In Use and deHaen Drugs in Research by 
obtaining the number of references for questions in five different 
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clinical areas (general information on new drugs, comparative efficacy 
studies, adverse drug reactions, bi©pharmaceutics and pharmacokinetics),  
and the amount of time for each search. In their results they indicated 
that i t  was apparent that I.D.I.S. has the highest relative utility for 
obtaining clinical drug information. The two deHaen services provided 
broad coverage of the primary clinical literature, whereas I.P.A. was 
effective in locating many useful drug information references (34). 
Cluxton et al.  compared quantitatively and qualitatively the usefulness 
of five information services in producing citations on the bioavaila­
bility of the oral dosage forms of five drugs. They indicated that 
I.P-.I.S. and the deHaen service had the lowest number of citations with 
intermittent search time, MEDLINE was the most efficient service, I.P.A. 
had the highest percent of unique citations, and Index Medlcus provided 
the highest number of citations but required more search time (35). 
In 1973 Cardoni made a comparison of Current Contents'  Life Sciences 
and Clinical Practice by determining the relative benefits derived from 
each service by hospital pharmacists.  He concluded that the use of 
either service was an efficient and economical method of keeping abreast 
of the current literature of hospital and clinical pharmacy (36). 
Madden and MacDonald quantitatively evaluated nine drug information 
services by obtaining the total number of citations for each of ten 
drugs, and the degree of overlap between those services used in the 
study. Their qualitative analysis was based upon the number of relevant 
references for three drugs and the degree of overlap. They indicated 
that with respect to computerized services, Excerpta Medica Drugdoc (EMD) 
provided the most comprehensive and complete coverage of the drug litera­
ture. Medlars complemented EMD and therefore should be used in combination. 
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ToxTine was considered unsuitable. In the case of manual services, 
I.D.I.S. was the most comprehensive. However, a combination of 1.0.1.S.,  
Index Medicus and Drug Literature Index would provide the most compre­
hensive search. The deHaen Drugs In Use was found to be unsuitable (37). 
Fortner et al.  reviewed 100 abstracts of deHaen Drugs in Use service 
to determine the reliability of this drug information service. They con­
cluded that the subscriber is urged to use the deHaen Drugs In Use 
abstracts as a means of l i terature access only, and not as a primary 
source of drug information due to the high error rate of abstracts (38). 
In 1978 Milne compared the usefulness of I.D.I.S. and MEDLINE 1n meeting 
the needs of a hospital-based drug information service and indicated that 
I.D.I.S. should be used since i t  provides the full article, while MEDLINE 
should be reserved for questions that cannot be answered by I.D.I.S. (39). 
Oncology as a Developing Specialty 
in Pharmacy 
The increasing use of antineoplastic agents has led to the necessity 
for pharmacists to specialize and to be responsible for these agents. In 
recent years clinical pharmacy services have been offered in oncology 
patient care areas. As a specialist,  the oncology pharmacist started to 
provide many services to patients and physicians as described by See and 
Bergquist in 1976 (40) which include: 
1. Drug Histories. The pharmacist can provide the physician with 
information about the patient 's past and present medications, allergies, 
and side effects of antineoplastic agents. 
2. Monitoring Drug Therapy. The pharmacist plays a role in monitor­
ing drug therapy, e.g.,  cumulative drug toxicity, therapeutic incompati­
bility, drug interactions, liver and renal function, and calculation of 
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dosage. The pharmacist can also monitor chemotherapeutlc agents'  
responses and toxicities. 
3. Patient Drug Profiles. For each patient a drug profile can be 
prepared by the pharmacist.  Data to be included in the profile include 
the patient history, laboratory data, past drug therapy, past progress 
notes, current therapy and patient response. 
4. Drug Therapy Consultations. These drug consultations are impor­
tant for cancer patients due to the severity of their conditions and the 
toxicities associated with their therapy. The patient should be counseled 
on side effects of the antineoplastic agents, drugs and food that may 
interact with his medications, his drug regimen, and any other changes 
that may occur during chemotherapy. 
5. Coordination Between the Pharmacist and Physician. The physician 
who anticipates the treatment of a cancer patient may not be familiar with 
the patient 's antineoplastic agents, especially their toxicities or pharm­
acological properties. The oncology pharmacist can provide drug informa­
tion, as needed. Additionally, the oncology pharmacist can help insure 
that the antineoplastic agents are available in local pharmacies and 
hospitals.  
6. Drug Information Source. A special drug information problem 
exists with cancer chemotherapy due to the nufrtber of investigation chemo-
therapeutic agents in use. This problem can be solved by the oncology 
pharmacist serving as a source of drug information concerning the stabil­
ity, toxicity, adverse effects, pharmacology, and dosing of the investi­
g a t i o n a l  a n d  n o n - i n v e s t i g a t i o n a l  a n t i n e o p l a s t i c  a g e n t s .  A d d i t i o n a l l y ,  a l l  
dosage calculations made by the physician may be checked by the pharma­
cist.  Laboratory indices which include blood counts, bone marrow analysis 
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and liver and renal function tests, are used by the oncology pharmacist 
(41). Kitzman and Martinson reported in 1981 that more information 
about cancer chemotherapeutic agents was desired by patients. They 
concluded that pharmacists have filled an information gap by providing 
drug information to cancer patients and family members about a group of 
antineoplastic drugs that had been poorly understood by the public (42). 
7. Inservice Education. The oncology pharmacist can provide educa­
tion to professionals and patients about the administration, dosage, side 
effects, and any other new information regarding the antineoplastic 
agents. Blumer emphasized in her study that the education of pharmacists 
"must expand beyond drugs. It must include an indepth understanding of 
the disease state and care of the cancer patient in order to be of maxi­
mum benefit to the health care team" (43). In addition the oncology 
pharmacist can offer many services such as preparation of chemotherapy 
and coordination of its administration, and supervision of outpatient 
treatment facilities." 
The oncology pharmacist can expand his service to include partici­
pation in clinical research and protocol development. He/she may par­
ticipate in the clinical testing of investigational drugs and disseminate 
information on investigational drugs and protocols to the clinician, 
medical center staff, and community practitioners (44). Furthermore, a 
specially trained oncology pharmacist can assist the dietician in iden­
tifying patients' nutritional problems, recommending food supplements, 
and restructuring their diets to insure adequate nutrition (45). Kellick 
et al. wrote in their study that the addition of pharmacists to this area 
(oncology) would bring continuity and organization to the use of anti­
neoplastic agents, decrease the length of time a patient must spend in 
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the hospital,  and provide an important safeguard against medication 
errors (46). 
A special medical oncology training program is offered by the Uni­
versity of Tennessee (47). The goal of this program 1s to prepare the 
oncology pharmacist for expanded services to oncology patients. These 
include instruction concerning the clinical application of antineoplastic 
agents, improved conmunication, and comprehensive cancer management. In 
addition to the treatment phase of cancer management, the oncology pharma­
cist may also contribute to other phases including etiology, prevention, 
detection, rehabilitation, and continuing care. These services may 
decrease morbidity and mortality in cancer patients in nonurban communi­
t ies by improving the detection and treatment of cancer in i ts early 
stages. 
Purpose of the Study 
An increasing number of pharmacists are specializing in the treatment 
of cancer patients due to the increasing body of knowledge in oncology. 
Because of the growth of the drug literature related to oncology, this 
study is designed to determine the usefulness of three drug information 
services as a source of information on investigational antineoplastic 
agents. The study is designed to evaluate I.P.A., I .0.I.$•» and deHaen 
Drugs In Use service quantitatively and qualitatively. No study has been 
published to date evaluating the utility of these three services as 
information sources for investigational antineoplastic agents. I_.D.I.S• 
and deHaen Drugs In Use service are selected for evaluation because they 
are in common usage as clinical drug information services, j .P.A. is 
selected because i t  is the primary pharmaceutical abstracting service in 
the U.S. 
18 
If these three services are effective in providing general informa­
tion concerning investigational cancer chemotherapeutic agents, i t  could 
prevent the necessity of using or purchasing additional, alternative, or 
more costly information services. Further, by determining which service 
is the most appropriate source of information on cancer chemotherapy, 
the pharmacist may be able to obtain information more efficiently. 
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Methodology 
This study was designed to measure the comparative utility of three 
indexing and abstracting drug information services in providing data 
about antineoplastic agents. The three services studied were deHaen 
Drugs In Use, Iowa Drug Information Service (I.D.I.S.}, and International 
Pharmaceutical Abstracts (I.P.A.). 
Description of the Three Services 
deHaen Drugs In Use (43,49). This service was established by Paul 
deHaen who started its publication in 1964 as one of three services. 
The other two services are: deHaen Drugs In Research and deHaen Drugs In 
Prospect. deHaen Drugs In Use reviews 1000 journals and abstracts about 
7,500 articles. These abstracts are found on microfiche cards. Each 
abstract consists of information obtained from the original article, 
including number of patients in the study, study design, dosage, route 
of administration, special description related to the subject (e.g.,  age, 
sex, and the disease state),  purpose of the study, adverse reactions, 
laboratory values and the author's comment and conclusion. 
The annual subscription rate for deHaen Drugs In Use is $1095. An 
additional fee is charged for the computerized index that is available. 
The lag time, or time period from publication of the original article 
to the appearance of the abstract in deHaen Drugs In Use, is four to 
five months. 
Iowa Drug Information Service (I.D.I.S.) (48,50). I .D.I.S. was 
developed by William Tester and initiated in 1966. This service reviews 
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156 journals per year and Included 17,536 articles in 1980, These arti­
cles are related to drugs or drug therapy. The indexing information is 
printed in microfiche cards which are labeled and t i t led alphabetically 
by drug index terms or disease index terms. Other index terms are used 
in all  index cards including: t i t le,  author, microfilm number, source, 
and special codes called clinical descriptors, which are used to describe 
or define the article of interest.  The subscription cost is $900 per 
year and has a lag time of two to four months. However, I .D.I.5. has a 
unique feature in that i t  provides a microfiche copy of the original 
article. 
International Pharmaceutical Abstracts (I.P.A.) (48,51). I.P.A. 
abstracts 5,000 articles per year. These articles appear in 600 journals 
related to pharmaceutical science and practice. There are about twenty-
five sections in each issue on different topics concerning drug pharma­
ceutical properties such as formula and formulation, parenteral solutions, 
kinetics, adverse reactions, and drug evaluations. The first year of 
publication was 1964. Current subscription cost is $250 annually, and 
the service has a three to six months lag time. In 1970, I.P.A. compu­
terized i ts service to provide additional information, including the 
citation, complete abstract,  and index as a part of the Toxline service. 
Table 1 summarizes the features of these three information services. 
Quantitative Evaluation 
The quantitative evaluation was based on determining the total num­
ber of citations for antineoplastic drugs in each service per year and 
obtaining the total number of citations for five selected investigational 
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Table 2 


















The period of quantitative evaluation was 1980 and 1981. The investi­
gational antineoplastic agents studied were selected by the oncology 
pharmacy staff at the Veterans Administration Hospital,  Palo Alto, Cali­
fornia. 
Qualitative Evaluation 
This analysis was based on the ability of each service to give 
useful information related to the five antineoplastic agents previously 
described. These five antineoplastic agents are distributed by the 
National Cancer Institute (N.C.I.) and at the time of this study were 
classified as investigational agents by the Food and Drug Administration. 
Based upon the categories of questions commonly asked by the oncology 
medical staff at the V.A. hospital,  several types of questions were 
designed and used to qualitatively evaluate the three services. These 
categories of questions are listed in Table 3. 
The evaluation of each service and i ts ability to provide relevant 
drug information for each of the categories for each of the investiga­
tional agents was based solely on the abstract or index provided by each 
service. This method was used to test the ability of each service to 
give useful drug information from its abstract or index without reference 
to the primary literature. The first question used in this study was 
related to the dose of each agent, e.g.,  how many pg or mg should be used 
in treatment, and the frequency of administration. The second question 
was related to the ability of these services to provide information about 
the route of administration of the agents. The third question was 
designed to address the problem of side effects or adverse reactions to 
the investigational agents. In the fourth question citations were sought 
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Table 3 
The Seven Categories of Questions 
Used in Qualitative Analysis 
1. What is the dose of the antineoplastic 
agent? 
2. What is the route of administration? 
3. What are the side effects or adverse 
reactions? 
4. What is the mechanism of action? 
5. What is the pharmacokinetics? 
6. Is the agent used alone? 
7. Is the agent used in combination with 
other drugs? 
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related to the mechanism of action of each agent, including mechanism 
of action in vitro, in vivo or in human studies. The fifth type of ques­
tion concerned the pharmacokinetics for each agent, including metabolism, 
absorption, distribution, excretion, and half-life in animals or humans. 
The last two questions were related to the use of each agent alone or in 
combination with other drugs or treatment, e.g., radiotherapy. 
The method of identifying the citations related to the categories 
of the questions was based upon the unique design and the characteristics 
of each of the services. For example, to obtain the available citations 
for the seven questions using deHaen Drugs In Use service, the proprie­
tary name index, therapeutic classification index and data cards from 
January to December, 1980 and 1981 were examined. In I.D.I.S. the 
microfiche headers and the index frame of each microfiche were used to 
locate the drug or disease index term desired for 1980 and 1981. In 
contrast, the source of information from I.P.A. was the abstracts from 
January to December for each year. 
Several search terms were used for each agent in this study. These 
search terms included the generic name of the agent and its synonyms. 
These terms were used to gain access to relevant citations in each ser­
vice and are listed in Table 4. 
Quantitative Analysis of Data 
The number of citations for antineoplastics agents was totaled for 
each service in 1980 and 1981 and compared using a modification of the 
methods of Tourville and McLeod (34). Their method includes calculating 
the mean based upon the total number of citations in each service evalu­




1.  Amsa: 
2.  Etoposide: 
3.  Ifosfamide: 
1• Amsa 
2.  Amsacrine 
3.  Acridinylamine-anisidide and aniside 
4. M-Amsa 
5.  NSC-249992 
1.  E toposide 
2.  Epipodophyllotoxin 
3.  Vp -  16 
4. NSC-141540 
1.  Ifosfamide 
2.  Isophosphamide 
3.  Iso-endoxin 
4.  Asta-4942 
5.  Z-4942 
6.  NSC-109724 
4.  Tenyposide: 
5.  Vindesine: 
1.  Teniposide 
2.  Vm-26 
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using a relative data locating index to determine the mean by which the 
services can be compared. The relative data locating index was calcu­
lated by dividing the greatest number of citations of any service into 
the number of ditations from the service studied and multiplying by 100: 
Relative data locating index = "°" °f * 100 3 Greatest No. of citations of any 
service 
Qualitative Analysis of Data 
Qualitative analysis was based on the ability of each service to 
provide useful information related to seven questions about five anti­
neoplastic agents. The total number of the answers (citations) was col­
lected for each agent in each service. A nonparametric test, "Friedman 
Two-Way Analysis of Variance by Ranks," was used to determine 1f the 
number of citations differed significantly. The Friedman test converts 
each subject's scores to ranks. Then the sum of each column is obtained. 
By using Friedman's formula: x^ = nk(k+l) (k+l) 
where: 
k = the number of columns 
n = the number of subjects 
2 R - squared sum of column ranks 
X2 value can tell whether or not there is a significant difference among r 
ranks (52,53). If this value has a probability of 0.05 or less, (when 
k = 3 and n = 5, x2 has a critical value of 6.A) a post-hoc test may be 
used to determine which of the three services differs significantly 
from the other (54). In this test, a pair-wise difference is signifi­
cant if the interval bounded by $ ± y/ x2 Var ($) does not contain "0' 
where: 
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* =  I ak Rk 
and 
V a r  & =  "12 n1 }  E ak 
For all  pair wise comparisons is the coefficient of the compari­
son and ^ is the average rank. 
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Results 
The results of the quantitative analysis of the three services, 
deHaen Drugs In Use, Iowa Drug Information Service, and International 
Pharmaceutical Abstracts, are shown in Tables 5-7. 
Table 5 shows the total number of antineoplastic citations in each 
service. In 1980 deHaen Drugs In Use yielded 1304 citations, while 
I.D.I.S. and I.P.A. provided 436 and 347, respectively. In 1981, these 
three services provided 1400, 433, 427 antineoplastic citations for 
deHaen Drugs In Use, I .D.I.S.,  and I.P.A., respectively. Table 6 shows 
that the total number of citations in 1980 for the five selected inves­
tigational antineoplastic agents were: 45 in the deHaen service, 83 in 
I.D.I.S.,  and 5 in I.P.A. In 1981 deHaen provided 73 citations; I.O.I.S. 
115; and I.P.A. provided only 7 citations (see Table 7).  
The results of the qualitative analysis of the three services are 
shows in Tables 8, 9 and 10 where the total number of citations related 
to the seven questions for the five agents was obtained in 1980 and 1981. 
Statistical analysis of the data was done by two tests.  The first test 
was the Friedman Two-Way Analysis of Variance by Ranks, which was used to 
determine if  these three services were significantly different from each 
other. When this test was applied, i t  was found that the three services 
were significantly different (P < 0.05) in obtaining citations for the 
questions related to dose, route of administration, adverse reactions 
and single therapy in 1980 and 1981 (see Tables 11-16, 22). It  was found 
that these three services were significantly different (P < 0.05) in 
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obtaining information in 1981 about the agent when used in combination 
with other agents (see Table 24).  However, there was no difference 
(P > 0.05) between these three services in 1980 and 1981 in obtaining 
citations concerning mechanism of action (see Tables 17, 18) and pharma­
cokinetics (see Tables 19, 20).  In addition, there was no difference 
(P > 0.05) in obtaining information about the agents studied in combina­
tion with other agents in 1980. 
The second test was the post-hoc test which was applied to the data 
in those instances where there was a demonstrated significant difference 
between the three services.  The post-hoc test was used to determine, 
through pairwise comparison, which service was significantly different 
(P < 0.05) from the other. These results are l isted in Tables 11-16, 
21, 22, 24. In addition, Table 11 includes the sequence of calculations 
associated with the Friedman and post-hoc analysis.  
It was found that I.0.I.S. was significantly different (P < 0.05) 
from I.P.A. in obtaining citations in 1930 concerning dose, route of 
administration and adverse reactions of the five investigational anti­
neoplastic agents.  There was no significant difference (P > 0.05) between 
I.D.I.S. and the deHaen service or between deHaen service and I.P.A. for 
questions about dose, route of administration and adverse reactions in 
1980. In addition, it  was found that there was no significant difference 
(P > 0.05) between these three services in providing information related 
to mechanism of action, pharmacokinetics,  single or combination therapy 
questions in 1980. In 1981 it  was found that I.D.I.S. was significantly 
different (P < 0.05) from I.P.A. for questions related to route of 
administration, adverse reactions, and use of the agents alone. There 
was no significant difference (P > 0.05) between I.D.I.S. and the deHaen 
31 
service or between the deHaen service and I.P.A. for questions regarding 
route of administration, adverse reactions, and use of the agents alone. 
However, there was no significant difference (P > 0.05) between these 
three services in obtaining information related to dose, mechanism of 
action, pharmacokinetics and use of the agents in combination with other 
antineoplastic agents in 1981. 
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Table 5 
Total Number of Citations for Antineoplastic Agents 
in Each Service in 1980 and 1981 
deHaen 
























Number of Citations for the Five Agents 
in the Three Services in 1980 
No. of Citations No. of Citations No. of Citations 
Drug in deHaen in in 
Name Drugs in Use I .D.I.S. I .P.A. 
1.  Amsacrine 9 10 1 
2.  Etoposide 10 33 2 
3.  Ifosfamide 3 8 1 
4. Teniposide 6 17 -
5. Vindesine 17 15 1 
Total 45 83 5 
Relative data 54 100 6 
locating index 
Table 7 
Number of Citations for the Five Agents 
in the Three Services in 1981 
No. of Citations No. of Citations No. of Citations 
Drug in deHaen in in 
Name Drugs in Use I .D.I.S. I .P.A. 
1.  Amsacrine 18 24 2 
2 .  Etoposide 14 45 3 
3. Ifosfamide 10 12 1 
4.  Tempos ide 9 9 1 
5.  Vindesine 22 25 
Total 73 115 7 
Relative data 
locating index 
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Ranking the Three Services by Number of Citations 
Related to Dose for Each Agent 1n 1980 
Investigational T  a T  b T  c 
Agent ' l  T2 3 
1. Amsacrine 8 (2) 9 (3) 1 (D 
2. Etoposide 9 (2) 25 (3) - (D 
3. I f  os f  amide 1 (1.5) 5 (3) 1 (1.5) 
4. Teniposide 5 (2) 14 (3) - (1) 
5. Vindesine 16 (3) 11 (2) 1 (D 
I = 39 (10.5) 64 (14) 3 (5.5) 
a = deHaen Drugs in Use Service 
b = Iowa Drug information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 




Rk 10.5/5 = 2.1 
Friedman test:  
2 
X r  12 
nK (K •  1) 
12 
5.3.4 
0 . 2  
67.3 




|  (£ Rk2) -  3n (X + 1) 
(10.52  + 142  + 5.52) -  3.5.4 
(336.5) 60 
60 : 7.3 has probability 
-  Post-Hoc test:  
T1 " T2 
V = + 1 (2.1) -  1 (2.8) = -0.7 
var (9) . J a£ 
" i K f  0 2  +  (-D2  
=  —  2  = 0 4  
60 
Test = -0.7 ± /6.2*(0.4) = -0.7 ± 1.6 
=-0.7 ±1.6 = -2.3 to 0.9 Contain "0", Not significant 
T1 " T3 
'¥ = 1 
Test = 1 ± 1.6 = -0.6 to 2.6 Contain "0" -  Not significant 
T2 " T3 
? = 1.7 
Test = 1.7 ± 1.6 = 0.1 to 3.3 Does not contain "0" '  significant 
at P < 0.05. 
* Value "from table N of K = 3, N = 5 at 0.05 level 
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Table 12 
Ranking the Three Services by Number of Citations 
Related to Dose for Each Agent in 1981 
Investigational 
Agent V T b  ' 2  T C  '3 
1. Amsacrine^ 16 (2) 21 ( 3 )  2 (D 
2. Etoposlde 14 (2) 26 ( 3 )  - (1) 
3. I fos f amide 10 (3) 6 (2) 1 (1) 
4. Teniposide 8 (3) 7 (2) - (1) 
5. Vindesine 21 (2) 22 (3) - (1) 
Z  =  -69 (12) 82 (J 3) 3 (-5) 
-  Friedman test:  X* -  7.6 has P < 0.05 
-  Post-hoc test:  T1 ~ T2 No significant difference 
T 1  - T 3  No significant difference 





deHaen Drugs In Use Service 
Iowa Drug Information Service 
International Pharmaceutical Abstracts 
Values in each column are the numbers of citations with the ranking* 
listed in parenthesis. 
41 
Table 13 
Ranking the Three Services by Number of Citations Related to 
Route of Administration for Each Agent in 1980 
Investigational 





1. Amsacrine^ 6 (2) 9 (3) - (1) 
2. Etoposide 7 (2) 23 (3) - (1) 
3. Ifosfamide 2 (2) 5 (3) - (1) 
4. Teniposide 3 (2) 14 (3) - (D 
5. Vindesine 12 (3) 10 (2) - (D 
I = =30 01 )  61 (14) 0  (5 )  
- Friedman test: xj = 8.4 has P < 0.05 -
- Post-hoc test: T 1  - T 2  
T1 " T3 
No significant difference 
No significant difference 
T2 - T3 Significant difference (P < 0.05) 
a - deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 14 ft 
Ranking the Three Services by Number of Citations Related to 
Route of Administration for Each Agent in 1981 
Investigational 
Agent V T 
b  
'2 T ^ 3 
1. Amsacrine^ 14 (2) 15 (3) 1 (1) 
2. Etoposide 13 (2) 22 (3) -  (D 
3. Ifosfamide 9 (3) 6 (2) -  (1) 
4. Teniposide 6 (2.5) 6 (2.5) -  (1) 
5. Vindesine 21 (2) 24 (3) -  (1) 
E = 63 (11-5) 73 (13.5) 1 (5) 
Friedman test:  
Post-hoc test:  
X » 7.9 has P < 0.05 r  
T1 ~ T2 
T1 -T3 
No significant difference 
No significant difference 





deHaen Drugs In Use Service 
Iowa Drug Information Service 
Internationa] Pharmaceutical Abstracts 
Values in each column are the numbers of citations with the rankinas 
listed in parenthesis. 
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Table 15 
Ranking the Three Services by Number of Citations Related to 
Adverse Reactions for Each Agent in 1980 
Investigational 
Agents V T ^ '2 T 
c  
'3 
1. Amsacrine^ 8 (2) 9 (3) 1 (D 
2. Etoposide 7 (2) 22 (3) - (1) 
3. Ifosfamide 1 (1.5) 8 (3) T (1.5) 
4. Teniposide 5 (2) 14 (3) - (D 
5. Vindesine 10 (2) 14 (3) 1 (D 
Z = 31 (9.5) 67 (15) 3 (5.5) 
-  Friedman test:  Xp = 9-1 has P < 0.05 
-  Post-hoc test:  T1 ~ T2 No significant difference 
T^ -  T^ No significant difference 
^2 ~ ^3 Significant difference (P < 0.05) 
a = deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d -  Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 16 
Ranking the Three Services by Number of Citations Related to 
Adverse Reactions for Each Agent in 1981 
Investigational 





1. Amsacrine*1  17 (2) 20 (3 )  2 (1) 
2. Etoposide 13 (2) 29 (3 )  (1) 
3. Ifosfamide 9 (2.5) 9 (2.5) 1 (1) 
4. Teniposide 6  (2) 8 (3 )  1 (1) 
5. Vindesine 13 (2) 21 (3 )  (1) 
2 38 (10.5) 87 (14.5) 4 (5) 
-  Friedman test:  X* « 9. 1 has P < 0.05 
-  Post-hoc test:  T T - T 2  
T1 T3 
No significant difference 
No significant difference 
T 2 - T 3  Significant difference (P < 0.05) 
a =• r ieHaen Drugs In Use Service 
b = Iowa Drug Information Service 
e = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 17 
Ranking the Three Services by Number of Citations Related to 
Mechanism of Action for Each Agent 1n 1980 
Investigational 
Agent V T 5  '2 
1. Amsacrined  - (2) - (2) - (2) 
2. Etoposide - (2) - (2) - (2) 
3. I fos famide 1 (1.5) 2 (3) 1 (1.5) 
4. Teniposide - (1.5) 1 (3) - (1.5) 
5. Vindesine 1 (1.5) 2 (3) 1 (1.5) 
I  2 (8.5) 5 (13) 2 (8.5) 
2 -  Friedman test x r  = 2.7 has P > 0.05 
a -  deHaen Drugs In Use Se rvice 
b -  Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 18 
Ranking the Three Services by Number of Citations Related to 
Mechanism of Action for Each Agent in 1981 
Investigational T  a T  b T  c 
Agent ' l  l2 '3 
1. Amsacrine1^ (1.5) 1 (3) (1.5) 
2. Etoposide (1.5) 1 (3) -  (1.5) 
3. I fosfamide -  (2) -  (2) -  (2) 
4. Teniposide -  (2) -  (2) -  (2) 
5. Vindesine (1.5) 1 (3) -  (1.5) 
1 = 0  ( 8 . 5 )  3  ( 1 3 )  0  ( 8 . 5 )  
-  Friedman test x? -  2.7 has P > 0.05 r  
a -  deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 19 
Ranking the Three Services by Number of Citations Related to 
Pharmacokinetics for Each Agent in 1980 
Investigational T  a T  b T  c 
Agent ' l  'z l3 
1. Amsacrine^ 1 (1.5) 2 (3) 1 (1.5) 
2. Etoposide 1 (1.5) 2 (3) 1 (1.5) 
3. Ifosfamide 1 (3) - (1.5) (1.5) 
4. Teniposide (1-5) 2 (3) (1.5) 
5. Vindesine 1 (2.5) 1 (2.5) -  (1) 
2 = 4  ( 1 0 )  7  ( 1 3 )  2  ( 7 )  
-  Friedman test:  =  3.6 has P > 0.05 
a -  deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 20 
Ranking the Three Services by Number of Citations Related to 
Pharmacokinetics for Each Agent in 1981 
Investigational 





- T C  '3 
1. Amsacrine^ 1 (2) 1 (2) 1 (2) 
2. Etoposide 1 (2) 1 (2) 1 (2) 
3. Ifosfamide 1 (2) 1 (2) 1 (2) 
4. Teniposide 1 (2.5 1 (2.5) - (D  
5. Vindesine 3 (3) 1 (2) - (1) 
E 7 (11.5) 5 (10.5) 3 - (8) 
-  Friedman test:  xj; = ? .3 has P > 0.05 
a = deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 21 
Ranking the Three Services by Number of Citations Related to 
Single Therapy for Each Agent in 1980 
Investigational T  a T  b T  c 
Agent ll  J2 '3 
1. Amsacrine^ 9 (3) 2 (2) T 0) 
2. Etoposide 6 (2) 8 (3) - (1) 
3. Ifosfamide 1 (1.5) 3 (3) 1 (1.5) 
4. Teniposide 3 (2) 7 (3) - 0) 
5. Vindesine 15 (3) 12 (2) 1 0) 
Z = • 34 01.5) 32 (13) 3 (5.5) 
-  Friedman test:  x~ =  6.3 has P < 0.05 r  
-  Post-hoc test:  T-j -  T^ No significant difference 
T^ -  T^ No significant difference 
T2  - T3  No significant difference 
a = deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 22 
Ranking the Three Services by Nuntoer of Citations Related to 
Single Therapy for Each Agent in 1981 
Investigational 
Agent V T ^ 2 T C  '3 
1. Amsacrine^ 17 (2) 22 (3) 2 (1) 
2. Etoposide 
• 
6 (3) 5 (2) 1 (D 
3. I f  os f amide 3 (2) 6 (3) - (1) 
4. Teniposide 3 (2) 6 (3) 1 (D 
5. Vindesine 15 (2) 18 (3) - (D 
2 44 (11 ) 57 (14) 4 (5) 
-  Friedman test:  =  8.4 has P < 0.05 
Post-hoc test:  T^ -  T^ No significant difference 
T^ -  Tj No significant difference 
^2 ~ ^3 Significant difference (P < 0.05) 
a = deHaen Drugs In Use Service 
b = Iowa brug Information Service 
c = international Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 23 
Ranking the Three Services by Number of Citations Related to 
Combination Therapy for Each Agent in 1980 
Investigational 
Agent V T b '2 T C 3 
1. Amsacrine^ - (1.5) 8 (2) (1.5) 
2. Etoposide 4 (2) 25 (3) 2 CD 
3, Ifosfamide 2 (2) 5 (3) -  CD 
4. Teniposide 3 (2) 10 (3) - (1) 
5. Vindesine 2 (2) 3 (3) -  (D 
I = 11' (9.5) 51 (14) 2 (5.5) 
- Friedman test: xt = 3.3 has P > 0.05 r 
a = deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
listed in parenthesis. 
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Table 24 
Ranking the Three Services by Number of Citations Related to 
Combination Therapy for Each Agent in 1981 
Investigational 





1. Amsacrine^ 1 (2) 2 (3) (1) 
2. Etoposide 8 (2) 40 (3) 2 (1) 
3. Ifosfamide 7 (3) 6 (2) 1 (1) 
4. Teniposide 6 (3) 3 (2) (1) 
5. Vindesine 7 (2.5) 7 (2.5) (1) 
Z = 29 (12.5) 58 (12.5) 3 (5) 
2 -  Friedman test:  x r  =  7 
-  Post-hoc test:  Tj -  T2  
.5 has P < 0.05 
No significant difference 
No significant difference 
No significant difference 
a = deHaen Drugs In Use Service 
b = Iowa Drug Information Service 
c = International Pharmaceutical Abstracts 
d = Values in each column are the numbers of citations with the rankings 
l isted in parenthesis. '  
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Discussion 
This study used the abstract and index information of the three 
services as the principal means of evaluating and comparing them. For 
the quantitative analysis of these three services as a source of infor­
mation concerning antineoplastic agents, the overall total number of 
citations is shown in Table 5. deHaen Drugs In Use service was found 
to provide the highest number of citations in both 1980 and 1981. By 
using relative data locating index in this analysis which is calculated 
as: 
Relative data locating index = No. of citations of service studies .  
Greatest No. of citations of any 
service 
I.D.I.S. provided 436 citations (relative data locating index -  33.4) In 
1930, and 433 citations (relative data locating index = 30.9) in 1981. 
I.P.A. had 347 citations (relative data locating index = 26.6) for 1980, 
and almost the same relative data locating index, 30.5, in 1931 as I.D.I.S. 
deHaen Drugs In Use service had about three times the number of citations 
as I.D.I.S. or I.P.A. in 1980 and more than three times than either in 
1931. This impressive difference in the total number of antineoplastic 
agents citations may be due to the difference in the number of journals 
which have been abstracted or indexed by each service. The deHaen service 
abstracts 1000 journals, I .P.A., 600 journals, while I .D.I.S. indexes 
only 156 journals. I t  should be mentioned that these numbers of citations 
as shown in Table 5 represented all  citations that have been found in 
each service in each year, even though each citation may be listed more 
than once due to cross-indexing. It  was beyond the scope of this project 
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to devise a method to eliminate replicate listings of the same cita­
tions. 
Quantitative analysis of the data obtained from each service shows 
that there is a significant difference (P <0.05) between these three 
services in the total number of references for these five agents. 1.P.A. 
provided a limited number of reference citations when compared with 
I.D.I.S. or the deHaen service. Table 6 shows that in 1980 the total 
number of citations for the five investigational antineoplastic agents 
was 83 in I.D.I.S.,  45 in the deHaen service (relative data locating 
index = 54), and only 5 citations in I.P.A. (relative data locating 
index = 6).  In 1981, I.P.A. had 7 citations for the five investigational 
antineoplastic agents (relative data locating index * 6), while the 
deHaen service provided 73 citations (relative data locating index = 63), 
and I.D.I.S. contained 115 (see Table 7).  
The qualitative evaluation of these three services was based on the 
ability of each service to provide useful therapeutic information related 
to the five selected Investigational antineoplastic agents. Basic thera­
peutic information such as the dose, route of administration, and adverse 
reactions are important to the health care professionals as well as the 
patient.  The pharmacist as a source of drug information and as a dis­
penser of the medications should be well informed concerning such infor­
mation. In addition, the availability of a drug information service 
would be an excellent source of information for the pharmacist and other 
health care providers. I t  has been suggested that physicians and nurses 
do not provide the patients with adequate instructions related to their 
medication (13,55); atid the patients do not want to waste the physician's 
t i m e  b y  q u e s t i o n i n g  h i m  a b o u t  t h e i r  m e d i c a t i o n s  ( 1 3 ) .  L e a r y  e t  a l .  
i 
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reported that only 8.3 percent of patients in their study indicated that 
their physicians and nurses had explained their medication to them, even 
though 83.5 percent of the patients were suspected to be 1n danger due 
to problems related to self-administration of their medication at home 
(55). Furthermore, since non-prescription drugs for self-medlcation 
provide little information about their side effects, interaction with 
food or other drugs, and their dangers of use, access to drug information 
source would be helpful (56). 
Based upon the need for therapeutic information about antineoplastic 
agents this study evaluated these three services according to the number 
of reference citations provided by each service in response to seven 
questions related to each agent. Tables 11 and 12 show that with respect 
to dose, I.D.I.S. was the best source of information in both 1980 and 
1981, providing 64 and 82 citations respectively. The deHaen service 
had 39 citations 1n 1980 and 69 citations'in 1981. I.P.A. was the lowest, 
providing 3 citations in each of 1980 and 1981. I.D.I.S. provided the 
highest number of citations regarding the route of administration in 
1980 and 1981, 61 and 73 citations respectively. The deHaen service 
provided 30 and 63 citations in 1980 and 1981 respectively, while I.P.A. 
had no citations in 1980, and provided only one citation in 1931. There 
were more adverse reactions citations for the five investigational anti­
neoplastic agents in I.D.I.S. than deHaen service or I.P.A. Tables 15 
and 16 show that I.D.I.S. provided the highest number of citations. 
The deHaen service provided 31 and 58, while I.P.A. had 3 and 4 for 
1980 and 1981, respectively. The pharmacokinetics and mechanism of 
action questions had the lowest total number of citations in each service 
in each year. As shown in Tables 19 and 20, for 1980 and 1981, I.D.I.S. 
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provided 7 and 5, the deHaen service provided 4 and 7, and I.P.A. had 
2 and 3, respectively, for the pharmacokinetic question. For the mech­
anism of action question, the total nuntf>er of citations in I.D.I.S. 
was 5 and 3, in the deHaen service 2 and 0, and in l .P.A. 2 and 0 for 
1980 and 1981, respectively (see Tables 17 and 13). This finding can be 
explained by the fact that the five agents are still  under investigation, 
and there were no studies completed regarding their effects in certain 
cases of cancer diseases. Information about the five investigational 
antineoplastic agents when studied in combination with other agents or 
alone is shown in Tables 21-24. It  appeared that in both 1980 and 1981, 
the deHaen service and I.P.A. provided fewer citations related to combi­
nation therapy than for use of the agents alone. I.D.I.S. contained the 
highest number of citations for the agents studied in combination in 
1980 and 1981. 
Friedman Two-Way Analysis of Variance by Ranks test was applied 
to the data in this study to determine if  these three services were sig­
nificantly different in the total number of citations for each of the 
seven questions for each agent. If there was a significant difference, 
the Post-hoc test was then applied, providing a pairwise comparison of 
the three services. With respect to the question about dose, Table 11 
shows that there was a significant difference (P < 0.05) between I.D.I.S. 
and I.P.-A., but no significant difference (P > 0.05) between the deHaen 
service and l .P.A. or I.D.I.S. in 1930. In 1981 there was no significant 
difference (P > 0.05) between these three services. However, there was a 
significant difference (P < 0.05) between I.D.I.S. and I.P.A. in obtain­
ing information related to the route of administration in both 1980 and 
1931 as shown in Tables 13 and 14. There was no significant difference 
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(P > 0.05} between the deHaen service and I.D.I.S. or I.P.A. during 1980 
and 1981 for this question. There were similar statistical results for 
the three services concerning the adverse reactions question in 1980 and 
1981 (Tables 15 and 16). In addition, Tables 19 and 20 show that there 
was no significant difference (P > 0.05) between the three services 
regarding pharmacokinetics and mechanism of action of the five Investi­
gational antineoplastic agents in 1980 and 1981. In the case of studies 
which have been done related to the five agents used alone or in combi­
nation with other agents, there were no significant differences (P > 0.05) 
between these three services in 1980. In 1981 there was a significant 
difference (P < 0.05) between I.D.I.S. and I.P.A. and no significant 
difference (P > 0.05) between the deHaen service and I.D.I.S. or I.P.A. 
(Tables 21-24). 
These data and statistical analyses show the superiority of I.D.I.S 
in obtaining Information related to the selected five investigational 
agents studied. This finding is related to the special orientation of 
each service of these three services. I .P.I.5. concentrates on drug and 
drug therapy information, while the deHaen service focuses on the thera­
peutic use and efficacy, clinical pharmacology, and toxicology of single 
drugs, and I.P.A. provides abstracts of information related primarily to 
the traditional pharmaceutical sciences. 
These findings of data and statistical analyses are similar to those 
of Tourville and McLeod (34) who compared these three services by using 
clinical questions related to different clinical areas such as biopharma-
ceutics and toxicology, and indicated that I.D.I.S. has the highest rela­
tive utility for providing clinical drug information. Similar results 
were reported by Madden and MacDonald who evaluated and compared nine 
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drug information retrieval services (37), and found that I.O.I.S. was 
the most comprehensive manual service. I.D.I.S. provides a copy of the 
original article on microfiche which makes i t  more convenient for the 
user by not having to waste time searching for the original article in 
the l i terature. deHaen Drugs In Use provided good information concerning 
the five investigational antineoplastic agents„ It  was surprising, 
however, that there was no significant statistical difference between 
i t  and I.P.A., even though i t  had a higher total number of citations than 
I.p.A. for the antineoplastic agents and also for the selected five agents. 
These findings about the deHaen Drugs In Use service were similar to that 
of Tourville and McLeod who indicated that the deHaen service offered 
broad coverage of primary clinical literature. The results were differ­
ent from that of Madden and MacDonald who concluded that the deHaen 
service was unsuitable. I.P.A. was found to be of l i t t le value in pro­
viding information related to the five investigational antineoplastic 
agents. 
60 
Summary and Conclusion 
The need for drug information is increasing at a rapid rate. The 
pharmacist is fulfilling a role as a drug information specialist by 
providing information to the physician* nurse, patient,  and others. The 
establishment of clinically oriented drug information centers has in­
creased significantly since 1962 when the first drug information center 
was established. 
The clinical pharmacist as a specialist in oncology offers his 
services to the physician and patient by providing information related 
to approved and investigational chemotherapeutic agents, monitoring drug 
therapy, calculating the dosage, providing laboratory indices, and moni­
toring responses and toxicities. The clinical pharmacist can conduct drug 
therapy consultations with patients by explaining the toxicities of 
their medication, side effects, and the use of this medication. He also 
can be a drug information source related to cancer chemotherapeutic 
agents, their pharmacology, adverse reactions, dosing, toxicities, etc. 
Many studies have evaluated various drug information services, 
using methods and criteria to predict the value of the services for 
certain drug information needs. No published study has evaluated the 
usefulness of drug information services as a source for investigational 
antineoplastic agents. This present study was designed to compare deHaen 
Drugs In Use service, Iowa Drug Information Service (I.D. I.S.) and 
International Pharmaceutical Abstracts (I.P.A.) as a source of informa­
tion on investigational cancer chemotherapeutic agents. Quantitative 
and qualitative methods were used to compare and evaluate these three 
61 
services. The relative data locating Index for each service was used 
in the quantitative analysis In 1980 and 1981. Data show that there was 
a difference between the three services based upon the relative data 
locating Index in 1980 and 1981 for all  antineoplastic agents as well 
as the selected five investigational antineoplastic agents. 
Two statistical tests were used to analyze the qualitative data. 
The first was the Friedman Two-Way Analysis of Variance by Ranks test 
which was used to determine whether or not a significant difference 
existed between the three services in providing information related to 
each question. If there was a significant difference, a post-hoc test 
was then applied to determine which one of the three services was sig­
nificantly different from the others. The two tests (Friedman and post-
hoc analysis) showed that I.D.I.S. was significantly different from 
I.P.A. in both 1980 and 1981, whereas there was no significant difference 
between deHaen Drugs In Use service and I.D.I.S. or I.P.A. 1n both 1980 
and 1981. 
Based on: 
1. The quantitative analysis, which indicated that I.D.I.S. pro­
vided the highest number of citations regarding the five investigational 
antineoplastic agents; 
2. The qualitative analysis, which also indicated that I.D.I.S. was 
significantly better than I.P.A. (P < 0.05); 
3. The unique feature of I.D.I.S. in providing the full original 
article 1n i ts microfiche; and 
4. The lower costs of I.D.I.S. ($900) when compared to the deHaen 
service ($1095), 
i t  it  concluded that I.D.I.S. is more comprehensive and appropriate than 
the deHaen service or I.P.A. in obtaining information related to inves­
tigational antineoplastic agents. 
Because of the relatively large number of citations contained in 
the deHaen Drugs In Use service, it is recoirmended as a useful second 
choice in obtaining therapeutic information about the antineoplastic 
agents. Xzf.A. was found to be unsuitable as a source of information on 
investigational chemotherapeutic agents. 
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